cycloheximide has been researched along with squalestatin 1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chambers, C; Keller, RK; Ness, GC; Zhao, Z | 1 |
| Avner, R; Doolman, R; Harats, D; Ravid, T; Roitelman, J | 1 |
2 other study(ies) available for cycloheximide and squalestatin 1
| Article | Year |
|---|---|
Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver.
Topics: Animals; Anticholesteremic Agents; Bridged Bicyclo Compounds, Heterocyclic; Chromatography, High Pressure Liquid; Cycloheximide; Enzyme Inhibitors; Farnesol; Farnesyl-Diphosphate Farnesyltransferase; Half-Life; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Liver; Lovastatin; Male; Mevalonic Acid; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Time Factors; Tricarboxylic Acids | 1996 |
The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Animals; beta-Galactosidase; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cholesterol; Cricetinae; Cycloheximide; Cysteine Proteinase Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Leupeptins; Lovastatin; Oligopeptides; Peptide Hydrolases; Precipitin Tests; Proteasome Endopeptidase Complex; Recombinant Fusion Proteins; Tricarboxylic Acids; Ubiquitins | 2000 |